Display options
Cite
Simons PIHG, Cornelissen MEB, Valkenburg O, et al. Causal relationship between polycystic ovary syndrome and coronary artery disease: A Mendelian randomisation study. Clin Endocrinol (Oxf). 2021;doi: 10.1111/cen.14593.
Simons, P. I. H. G., Cornelissen, M. E. B., Valkenburg, O., Onland-Moret, N. C., van der Schouw, Y. T., Stehouwer, C. D. A., Burgess, S., & Brouwers, M. C. G. J. (2021). Causal relationship between polycystic ovary syndrome and coronary artery disease: A Mendelian randomisation study. Clinical endocrinology, . https://doi.org/10.1111/cen.14593
Simons, Pomme I H G, et al. "Causal relationship between polycystic ovary syndrome and coronary artery disease: A Mendelian randomisation study." Clinical endocrinology vol. (2021). doi: https://doi.org/10.1111/cen.14593
Simons PIHG, Cornelissen MEB, Valkenburg O, Onland-Moret NC, van der Schouw YT, Stehouwer CDA, Burgess S, Brouwers MCGJ. Causal relationship between polycystic ovary syndrome and coronary artery disease: A Mendelian randomisation study. Clin Endocrinol (Oxf). 2021 Sep 15; doi: 10.1111/cen.14593. Epub 2021 Sep 15. PMID: 34524719.
Copy Download .nbib Format: NLM
Share it on

Clin Endocrinol (Oxf). 2021 Sep 15; doi: 10.1111/cen.14593. Epub 2021 Sep 15.

Causal relationship between polycystic ovary syndrome and coronary artery disease: A Mendelian randomisation study.

Clinical endocrinology

Pomme I H G Simons, Merel E B Cornelissen, Olivier Valkenburg, N Charlotte Onland-Moret, Yvonne T van der Schouw, Coen D A Stehouwer, Stephen Burgess, Martijn C G J Brouwers

Affiliations

  1. Department of Internal Medicine, Division of Endocrinology and Metabolic Diseases, Maastricht University Medical Center, Maastricht, The Netherlands.
  2. Laboratory for Metabolism and Vascular Medicine, Maastricht University, Maastricht, The Netherlands.
  3. CARIM School for Cardiovascular Diseases, Maastricht University, Maastricht, The Netherlands.
  4. Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands.
  5. Department of Reproductive Medicine, Maastricht University Medical Center, Maastricht, The Netherlands.
  6. Department of Internal Medicine, Division of General Internal Medicine, Maastricht University Medical Center, Maastricht, The Netherlands.
  7. Department of Public Health and Primary Care, University of Cambridge, Cambridge, UK.
  8. MRC Biostatistics Unit, University of Cambridge, Cambridge, UK.

PMID: 34524719 DOI: 10.1111/cen.14593

Abstract

OBJECTIVE: Polycystic ovary syndrome (PCOS) has been associated with an increased risk of coronary artery disease (CAD). However, it remains uncertain whether this increased risk is the result of PCOS per se or, alternatively, is explained by obesity, a common feature of PCOS. The aim of this study was to assess the causal association between PCOS and CAD and the role of obesity herein.

DESIGN AND METHODS: We conducted two-sample Mendelian randomisation analyses in large-scale, female-specific datasets to study the association between genetically predicted (1) risk of PCOS and risk of CAD, (2) body mass index (BMI) and risk of PCOS and (3) BMI and risk of CAD. Primary analyses were conducted with the inverse-variance weighted (IVW) method. Simple median, penalized weighted median and contamination mixture analyses were performed to assess the robustness of the outcomes.

RESULTS: IVW analyses did not show a statistically significant association between PCOS and CAD (odds ratio [OR]: 0.99, 95% confidence interval [CI]: 0.89, 1.11). In contrast, genetically predicted BMI was statistically significantly associated with an increased odds of PCOS (OR: 3.21, 95% CI: 2.26, 4.56) and CAD (OR: 1.38, 95% CI: 1.14, 1.67). Similar results were obtained when secondary analyses were performed.

CONCLUSION: These sex-specific analyses show that the genetically predicted risk of PCOS is not associated with the risk of CAD. Instead, the genetically predicted risk of obesity (and its downstream metabolic effects) is the common denominator of both PCOS and CAD risk.

© 2021 The Authors. Clinical Endocrinology Published by John Wiley & Sons Ltd.

Keywords: Mendelian randomisation; coronary artery disease; obesity; polycystic ovary syndrome

References

  1. Wolf WM, Wattick RA, Kinkade ON, Olfert MD. Geographical prevalence of polycystic ovary syndrome as determined by region and race/ethnicity. Int J Environ Res Public Health. 2018;15(11):2589. - PubMed
  2. De Groot PC, Dekkers OM, Romijn JA, Dieben SW, Helmerhorst FM. PCOS, coronary heart disease, stroke and the influence of obesity: a systematic review and meta-analysis. Hum Reprod Update. 2011;17(4):495-500. - PubMed
  3. Lim SS, Davies MJ, Norman RJ, Moran LJ. Overweight, obesity and central obesity in women with polycystic ovary syndrome: a systematic review and meta-analysis. Hum Reprod Update. 2012;18(6):618-637. - PubMed
  4. Hemani G, Bowden J, Davey Smith G. Evaluating the potential role of pleiotropy in Mendelian randomization studies. Hum Mol Genet. 2018;27(R2):R195-R208. - PubMed
  5. Zhu T, Cui J, Goodarzi MO. Polycystic ovary syndrome and risk of type 2 diabetes, coronary heart disease, and stroke. Diabetes. 2020;70:627-637. - PubMed
  6. Liu LY, Schaub MA, Sirota M, Butte AJ. Sex differences in disease risk from reported genome-wide association study findings. Hum Genet. 2012;131(3):353-364. - PubMed
  7. Day F, Karaderi T, Jones MR, et al. Large-scale genome-wide meta-analysis of polycystic ovary syndrome suggests shared genetic architecture for different diagnosis criteria. PLoS Genet. 2018;14(12):e1007813. - PubMed
  8. Bowden J, Del Greco M F, Minelli C, et al. Improving the accuracy of two-sample summary-data Mendelian randomization: moving beyond the NOME assumption. Int J Epidemiol. 2019;48(3):728-742. - PubMed
  9. Burgess S, Thompson SG, Collaboration CCG. Avoiding bias from weak instruments in Mendelian randomization studies. Int J Epidemiol. 2011;40(3):755-764. - PubMed
  10. Locke AE, Kahali B, Berndt SI, et al. Genetic studies of body mass index yield new insights for obesity biology. Nature. 2015;518(7538):197-206. - PubMed
  11. Sudlow C, Gallacher J, Allen N, et al. UK Biobank: an open access resource for identifying the causes of a wide range of complex diseases of middle and old age. PLoS Med. 2015;12(3):e1001779. - PubMed
  12. Burgess S, Bowden J, Fall T, Ingelsson E, Thompson SG. Sensitivity analyses for robust causal inference from Mendelian randomization analyses with multiple genetic variants. Epidemiology. 2017;28(1):30-42. - PubMed
  13. Bowden J, Davey Smith G, Haycock PC, Burgess S. Consistent estimation in Mendelian randomization with some invalid instruments using a weighted median estimator. Genet Epidemiol. 2016;40(4):304-314. - PubMed
  14. Burgess S, Foley CN, Allara E, Staley JR, Howson JMM. A robust and efficient method for Mendelian randomization with hundreds of genetic variants. Nat Commun. 2020;11(1):376. - PubMed
  15. Slob EAW, Burgess S. A comparison of robust Mendelian randomization methods using summary data. Genet Epidemiol. 2020;44(4):313-329. - PubMed
  16. Verbanck M, Chen C-Y, Neale B, Do R. Detection of widespread horizontal pleiotropy in causal relationships inferred from Mendelian randomization between complex traits and diseases. Nat Genet. 2018;50(5):693-698. - PubMed
  17. Hemani G, Bowden J, Haycock P, et al. Automating Mendelian randomization through machine learning to construct a putative causal map of the human phenome. bioRxiv. 2017. - PubMed
  18. Hemani G, Zheng J, Elsworth B, et al. The MR-Base platform supports systematic causal inference across the human phenome. eLife. 2018;7(e34408). - PubMed
  19. Yavorska OO, Burgess S. MendelianRandomization: an R package for performing Mendelian randomization analyses using summarized data. Int J Epidemiol. 2017;46(6):1734-1739. - PubMed
  20. Dina C, Meyre D, Gallina S, et al. Variation in FTO contributes to childhood obesity and severe adult obesity. Nat Genet. 2007;39(6):724-726. - PubMed
  21. Zhang J, Xu J-H, Qu Q-Q, Zhong G-Q. Risk of cardiovascular and cerebrovascular events in polycystic ovarian syndrome women: a meta-analysis of cohort studies. Front Cardiovasc Med. 2020;7:552421. - PubMed
  22. Ramezani Tehrani F, Amiri M, Behboudi-Gandevani S, Bidhendi-Yarandi R, Carmina E. Cardiovascular events among reproductive and menopausal age women with polycystic ovary syndrome: a systematic review and meta-analysis. Gynecol Endocrinol. 2020;36(1):12-23. - PubMed
  23. Brower MA, Hai Y, Jones MR, et al. Bidirectional Mendelian randomization to explore the causal relationships between body mass index and polycystic ovary syndrome. Hum Reprod. 2018;34(1):127-136. - PubMed
  24. Larsson SC, Bäck M, Rees JMB, Mason AM, Burgess S. Body mass index and body composition in relation to 14 cardiovascular conditions in UK Biobank: a Mendelian randomization study. Eur Heart J. 2020;41(2):221-226. - PubMed
  25. Zhao Y, Xu Y, Wang X, et al. Body mass index and polycystic ovary syndrome: a 2-sample bidirectional Mendelian randomization study. J Clin Endocrinol Metab. 2020;105(6):dgaa125. - PubMed
  26. Fabbrini E, Sullivan S, Klein S. Obesity and nonalcoholic fatty liver disease: biochemical, metabolic, and clinical implications. Hepatology. 2010;51(2):679-689. - PubMed
  27. Selva DM, Hogeveen KN, Innis SM, Hammond GL. Monosaccharide-induced lipogenesis regulates the human hepatic sex hormone-binding globulin gene. J Clin Invest. 2007;117(12):3979-3987. - PubMed
  28. Telgenkamp I, Kusters Y, Schalkwijk CG, et al. Contribution of liver fat to weight loss-induced changes in serum hepatokines: a randomized controlled trial. J Clin Endocrinol Metab. 2019;104(7):2719-2727. - PubMed
  29. Ruth KS, Day FR, Tyrrell J, et al. Using human genetics to understand the disease impacts of testosterone in men and women. Nat Med. 2020;26(2):252-258. - PubMed
  30. Brouwers MCGJ, Simons N, Stehouwer CDA, Koek GH, Schaper NC, Isaacs A. Relationship between nonalcoholic fatty liver disease susceptibility genes and coronary artery disease. Hepatol Commun. 2019;3(4):587-596. - PubMed
  31. Brouwers MCGJ, Simons N, Stehouwer CDA, Isaacs A. Non-alcoholic fatty liver disease and cardiovascular disease: assessing the evidence for causality. Diabetologia. 2020;63(2):253-260. - PubMed
  32. Cerda C, Pérez-Ayuso RM, Riquelme A, et al. Nonalcoholic fatty liver disease in women with polycystic ovary syndrome. J Hepatol. 2007;47(3):412-417. - PubMed
  33. Lim SS, Norman RJ, Davies MJ, Moran LJ. The effect of obesity on polycystic ovary syndrome: a systematic review and meta-analysis. Obes Rev. 2013;14(2):95-109. - PubMed

Publication Types

Grant support